Exploring New Advancements in ADC Technologies (CPHI Milan 2024)

At CPHI Milan 2024, Nicolas Camper, Senior Director of Bioconjugation Chemistry at Abzena, spoke about new developments in ADC technologies, including the role of complex chemistries.

Nicolas sat with the Pharmaceutical Technology Group during CPHI Milan to discuss advancements in conjugation and linker technologies in antibody-drug conjugate (ADC) development and manufacturing.

“There have been a lot of new developments in terms of conjugation and linker technologies. There is a definitive move towards site-specific conjugation technologies and away from stochastic conjugation approaches that allows [us] to prepare better-defined antibiotic-[drug] conjugates.”

Another new development that has been observed over the past few years is that linkers are becoming more sophisticated…

“Quite often, when you conjugate cytotoxic drugs, they are quite hydrophobic, and that can impact the performance of your ADC. So, there has been a lot of effort put into developing more hydrophilic linkers.”

Read the full article on biopharminternational.com.

Discover Bioconjugate & ADC Services